Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Results presented at the European Society of Cardiology Congress from the phase 3 trial demonstrated a 27% drop in hospitalisation risk

Lilly BI logosResults from the EMPEROR-Preserved phase 3 trial have demonstrated that empagliflozin, which is sold as Jardiance by Boehringer Ingelheim and Eli Lilly, showed a “significant” 21% relative risk reduction in the composite primary endpoint of cardiovascular death or hospitalisation for heart failure in adults with heart failure with preserved ejection fraction.

Empagliflozin also reduced the relative risk of first and recurrent hospitalisations for heart failure by 27% and significantly slowed kidney function decline.

Results from the phase 3 EMPEROR-Preserved trial were presented on 27 August 2021 at the European Society of Cardiology Congress and published in The New England Journal of Medicine.

“There are currently no clinically proven treatments we can offer people living with HFpEF that can have such a positive impact on their condition or reduce their chances of being admitted to hospital for heart failure,” said Iain Squire, professor of Cardiovascular Medicine at the University of Leicester, and Lead Investigator for EMPEROR-Preserved in the UK.

"Data from the EMPEROR-Preserved trial firmly establishes the potential for a new treatment for HFpEF patients in the UK and Ireland. The primary endpoint demonstrated benefit for patients with ejection fraction above 40% and was consistent across further subgroups, including men and women, as well as those with and without diabetes, which underlines empagliflozin’s potential for improvement in patients’ quality of life and outcomes.”

The heart failure market is becoming increasingly competitive, with Jardiance’s positive results in the EMPEROR-Reduced trial competing with AstraZeneca’s heart failure drug Farxiga, which scored an FDA fast-track designation in September 2020.

Article by
Bryony Andrews

31st August 2021

From: Research, Regulatory, Healthcare

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...